SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Elon Musks warning that neocloud providers face failures and consolidation has intensified selling in CoreWeave and renewed concern about its debt-heavy, capital-intensive AI infrastructure model and access to financing. Traders debate whether Musk is criticizing a competitor for self-interest, while bulls point to AI demand and Nvidias backing and bears focus on borrowing costs, dilution, and execution risks.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure alongside AI data-center and neocloud stocks as traders debate financing risks and Elon Musks warning that tighter credit could trigger failures among smaller operators. Bears fear debt, dilution and execution challenges, while bulls argue IRENs contracts, power access and AI partnerships distinguish it and point to continued compute demand.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp neocloud selloff tied to Elon Musks warning of tighter financing and consolidation among AI infrastructure providers, intensifying concerns about debt-funded expansion and data-center returns. Traders disagree on whether Nebius is vulnerable to sector-wide risks or better positioned because of its financing access and demand for AI compute.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

Brazils presidential runoff result, with Lula defeating Flvio Bolsonaro, is driving attention as traders react to a sharp selloff and uncertainty over the countrys economic outlook. Some are bearish and question the election, while others view the drop as a buying opportunity or are positioning for further volatility.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Phase 3 melanoma-vaccine results with Merck are driving discussion: traders broadly view the data as clinically promising, but the shares sold off as investors judged them against high expectations after a sharp rally. Bulls see validation for a broader cancer-vaccine platform, while bears question its commercial potential, costs and valuation.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is caught in a broad selloff in AI data-center and neocloud stocks, as traders debate debt, financing costs, and whether the sectors expansion can generate returns. Some see the decline as a buying opportunity, pointing to insider purchases and contracted growth; speculation about future hyperscaler deals and enthusiasm around AI spending compete with concerns about execution and dilution.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Trumps statement that the U.S. would not strike Iran has fueled debate over a futures bounce, while traders remain concerned about unresolved conflict risks and elevated oil prices. The community is split between dip-buyers and bears focused on inflation, the Fed decision, and major tech earnings as sources of continued volatility.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on SELLASs REGAL Phase 3 trial of GPS for AML, with traders watching for the 80th survival event that would trigger final analysis and eventual topline results. The prolonged wait and company silence fuel debate: bulls speculate that slower event accrual reflects longer survival and possible ASH-related disclosure, while skeptics warn that the delay is uncertain and could signal problems; SLS009 data is a secondary focus.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Lulas election victory over Flvio Bolsonaro has put Petrobras political exposure in focus, with traders debating whether a less market-friendly government could weigh on the stock. Some worry about government influence on pricing and shareholder returns, while others argue that strong oil economics could cushion the impact.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings strong quarterly results, including record profitability and continued growth, are driving bullish attention, with traders praising the business momentum. Some remain cautious about credit quality and the stocks volatile price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

US tariffs on metals and pharma: Which Indian stocks are safe and which aren't: Sudip Bandyopadhyay

Indian equity markets face policy risks from US tariffs and West Asia conflict. These issues impact metals and pharmaceutical sectors. Expert Sudip Bandyopadhyay provides stock-specific insights. Vedanta and NALCO are well-positioned in aluminium. Tata Steel faces uncertainty due to European operations. Sun Pharma and Glenmark are at risk in the pharmaceutical sector due to branded drug exposure.

Indian Bank, Cummins, Glenmark Pharma: 3 stocks ideas for near-term gains, check targets

… suggested three stocks including Glenmark Pharmaceuticals Ltd, Cummins India and Indian … , supporting further upside potential. Glenmark Pharmaceuticals | Buy | Target Price: Rs 2 … Loss: Rs 1,988 Glenmark Pharma is displaying a constructive bullish setup …

Glenmark Pharmaceuticals Launches GLIPIQ® (Semaglutide) In India

… (Glenmark), a research-led, global pharmaceutical company, today announced the launch of … been approved by the Central Drugs Standard Control Organization (CDSCO) … Business Head, India Formulations, Glenmark Pharmaceuticals Ltd., said, "Affordability …

Glenmark Debuts Budget Semaglutide In India, Undercutting Ozempic By Over 80%

Equity

As the patents for semaglutide near expiry in several countries this month, India has introduced a cost-effective alternative.


Rs 325–4,200/month: Dr Reddy’s, Sun Pharma, Glenmark kick off generic semaglutide price war

… Reddy’s Laboratories, Sun Pharma , Glenmark Pharmaceuticals , Alkem Laboratories, Zydus Lifesciences … , and Natco Pharma . Eris Lifesciences, which has a … first Indian pharma company to receive approval from the Drugs Controller General …

Sun Pharma, Dr Reddy's, Glenmark Launch Generic Semaglutide Injection in India

… markets." Another homegrown pharma major, Glenmark Pharmaceuticals Ltd also launched its …

Will Trump’s 100% Tariffs Derail Indian Pharma Stocks? SEBI Analyst Flags Key Levels For Traders

The new U.S. duty has already triggered a slide in major Asian pharma names, raising concerns about how Indian peers will react in the coming weeks.

Trading Radar For September 25: Tata Motors, Lupin, Glenmark, Polycab, Swan Defence Stocks Are On Investors’ Watchlist

Ivalue Infosolutions set to list on the mainboard today

Adani Ports, TCS, Glenmark Among SEBI Analyst’s Breakout Calls 

The analyst highlights breakout opportunities in these stocks, provided that critical support levels are maintained.

Glenmark Pharmaceuticals Shares Gain 3% After Launching Phase 3 Lung Cancer Drug Trial

The company has submitted a Clinical Trial Application to start the study in Russia and is preparing sites in Brazil and Mexico

Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. It operates through the following geographical segments: India, North America, Europe, Latin America, and Rest of the World. The company was founded by Gracias Saldanha on November 18, 1977 and is headquartered in Mumbai, India.

Glenmark Pharmaceuticals Ltd.

Neutral Sentiment

<ul class="summary-bullets"><li>Glenmark launched semaglutide under the brand name GLIPIQ for adults with Type 2 diabetes at ₹325 ($3.5) per week on Saturday.</li><li>The launch comes in a market where GLP-1 drugs such as Ozempic and Mounjaro are available at a much steeper cost.</li><li>The lower price point will reduce the cost barrier for diabetes and weight-loss treatment in India.</li></ul>As demand for diabetes and weight-loss treatments rises, Glenmark Pharmaceuticals Ltd (GLENMARK.NSE) has introduced a cost-effective version of semaglutide in India, aiming to improve affordability in a market dominated by higher-priced alternatives.Glenmark&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://glenmarkpharma.com/gpl_pdfs/media/PR_Glenmark%20Pharmaceuticals%20launches%20GLIPIQ%E2%93%87.pdf">launched</a> semaglutide under the brand name GLIPIQ for adults with Type 2 diabetes on Saturday, with weekly treatment costs starting at ₹325 ($3.5). The drug belongs to a class of medicines that help control blood sugar levels and are also used for weight management.The launch came in the market as GLP-1 drugs like Ozempic and Mounjaro are available at significantly higher prices. Weekly treatment using these can cost around ₹3,000 ($21) or more, depending on dosage and brand. At a more granular level, a 1 mg dose of Ozempic is priced near ₹12,000 ($128), while a 2.5 mg Mounjaro injection costs about ₹3,300 ($35).In comparison, GLIPIQ is priced between ₹325 and ₹440 ($3.5 to $4.7) per week, depending on dosage.Commenting on the launch, Alok Malik, President and Business Head, India Formulations at Glenmark Pharmaceuticals, said, “Affordability is one of the biggest barriers to initiating advanced diabetes treatment in India. With GLIPIQ, we are setting a new benchmark in affordability for GLP-1 drugs, with weekly treatment starting at ₹325.”<a href="https://stocktwits.com/symbol/GLENMARK.NSE/sentiment">GLENMARK.NSE</a> closed at ₹2,180 ($23.19) on Friday, trading up by almost 4%. On Stocktwits, the retail sentiment around GLENMARK.NSE improved from ‘neutral’ to ‘bullish,’ as chatter levels around it remained ‘normal’ over the past day.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_21_at_2_24_01_PM_png_9e2a9418ca.webp" alt="Screenshot 2026-03-21 at 2.24.01 PM.png" width="1160" height="684"><figcaption>StocktwitsGLENMARK.NSE retail sentiment on March 21 as of 2:42 a.m. ET | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Global GLP-1 Market</h2>The GLP-1 drug market has been dominated by Novo Nordisk (NVO) and Eli Lilly (LLY), whose products Ozempic and Monjaro are widely used for diabetes and weight management. However, patent expiries have reshaped the landscape.&nbsp;According to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-03-20/ozempic-copies-to-cost-14-in-india-as-generic-glp-1-era-starts">report</a>, Canada was among the first to lose patent protection for semaglutide earlier this year. The patent for semaglutide is also set to expire this month in China, Brazil, and Turkey. This positioned India as one of the first major markets to see the entry of lower-cost alternatives, as domestic drugmakers began launching competing products at a much lower cost.&nbsp;<h2 class="st-heading-2">How Is Stocktwits Reacting?</h2><stembedurl>https://www.stocktwits.com/TrendonomicsHD/message/648064809</stembedurl>One user on Stocktwits said that Glenmark is showing strong bullish technical signals despite a bearish sentiment. They pointed out that the stock appears to be in a "Stage 2 breakout," meaning it is starting to edge higher.Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-whale-who-called-crash-warns--debt-hits-wwii/cZ3i55RRIiW">Whale Who Shorted Bitcoin In Black Swan Event Warns As US Debt Hits Highest Since World War II</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. While some doctors are prescribing it "off label" for weight loss, on March 17, 2026 in Sydney, Australia. (Photo by Steve Christo/Getty Images)

As the patents for semaglutide near expiry in several countries this month, India has introduced a cost-effective alternative.

Current Price	2,166.60
Prev Close	2,198.50
Open	2,196.00
Dividend Yield	0.23%
50-Day Moving Average	2,356.28
Beta	0.03
Avg. Volume	558,727.29
PE Ratio	34.01

52-Week High	2,537.60
52-Week Low	1,792.60
Market Capitalization	601.03B
EPS (Annual)	48.26
Price to Book	5.82
Revenue Per Employee	9.55M

Feed

News

Sentiment

Earnings

Fundamentals

Info

GLENMARK.NSE Fundamentals